Virtual Presentation

Relapsed/Refractory Multiple Myeloma: Options for Subsequent Therapy

Source: Hematology Grand Rounds: Optimal Management Strategies and Novel Agents in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma: Options for Subsequent Therapy

Program Director: G. David Roodman, MD, PhD

Faculty:

Amitabha Mazumder, MD

CREDIT INFORMATION

Release Date: February 25, 2010

Expiration Date: February 24, 2011

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Registered Nurses: 0.6 Nursing contact hours

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent clinical trial data on the use of lenalidomide-containing regimens for the treatment of relapsed/refractory multiple myeloma
Cite results of clinical trials evaluating bortezomib-containing regimens in special populations including patients with renal insufficiency and poor cytogenetics
Describe new aspects of supportive care for patients with multiple myeloma
Discuss recent clinical trial data on the use of novel agents in combination with bortezomib- and lenalidomide-containing regimens

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.